Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

Phase 1CompletedNCT01226602

AstraZeneca39 enrolled

Overview

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Blood Flow Speed Coronary Flow Velocity

Interventions

AZD6140DRUG

P2Y12 receptor antagonist

PlaceboDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge * Have a body mass index between 18 and 30 kg/m2 Exclusion Criteria: * History of clinically significant disease or disorder. * Abnormal vital signs

Locations (1)

Research Site

Uppsala, Sweden

Outcomes

Primary Outcomes

Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug.

Time frame: During 6 h at visit 2

Time frame: During 6 h at visit 3

Secondary Outcomes

Effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity by estimating the change in area under the adenosine dose response curve before and after infusion of theophylline.

Time frame: During 6 h at visit 2

Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline.

Time frame: During 6h at visit 2

Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline.

Time frame: During 6 h at visit 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.